Clinical use of Cryoprecipitate
- Arthur J Silvergleid, MD
Arthur J Silvergleid, MD
- Section Editor — Transfusion Medicine
- Affiliate Associate Professor, Department of Pathology and Cell Biology
- University of South Florida, College of Medicine
- Medical Director, OneBlood, Inc.
Cryoprecipitate (Cryoprecipitated antihemophilic factor [AHF]; cryo) is the insoluble material that comes out of solution after frozen plasma is thawed at 4°C (between 1 and 6°C). It is rich in certain plasma proteins, especially fibrinogen.
This topic will discuss the clinical use of Cryoprecipitate. Use of other plasma products and plasma derivatives is discussed in separate topic reviews:
●Fresh Frozen Plasma (FFP) and other plasma products – (See "Clinical use of plasma components".)
●Plasma derivatives including coagulation factor concentrates – (See "Plasma derivatives and recombinant DNA-produced coagulation factors".)
●Fibrin sealant – (See "Fibrin sealants".)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Sørensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149:834.
- Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. Transfus Med 2012; 22:344.
- Yang L, Stanworth S, Baglin T. Cryoprecipitate: an outmoded treatment? Transfus Med 2012; 22:315.
- Gröner A. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9. Haematologica 2008; 93:e24.
- Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118:40.
- Schöchl H, Nienaber U, Maegele M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15:R83.
- Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104:555.
- O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.
- Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23:177.
- Hesselvik F, Brodin B, Carlsson C, et al. Cryoprecipitate infusion fails to improve organ function in septic shock. Crit Care Med 1987; 15:475.
- Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth 2014; 113:922.
- Galas FR, de Almeida JP, Fukushima JT, et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg 2014; 148:1647.
- Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64:S79.
- Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17:R76.
- Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303:1318.
- Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma. Transfus Apher Sci 2012; 46:153.
- Cid J, Caballo C, Pino M, et al. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion 2013; 53:600.
- Atance R, Pereira A, Ramírez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41:1548.
- Infusion rate
- Dosing interval
- CLINICAL USES
- Overview of uses
- Massive blood loss (eg, surgery, trauma)
- Inherited disorders of fibrinogen
- Impaired hemostasis in liver disease
- Disseminated intravascular coagulation
- Uremic bleeding
- CONDITIONS FOR WHICH CRYOPRECIPITATE IS INEFFECTIVE
- RISKS AND ADVERSE EVENTS
- SUMMARY AND RECOMMENDATIONS